UNIVERSITY OF KENT
MODULE SPECIFICATION TEMPLATE
SECTION 1: MODULE SPECIFICATIONS
1.
Title of the module
PHAM 1098 Applied therapeutics: Integrated Patient Care
2.
School which will be responsible for management of the module
Pharmacy
3.
Start date of the module
Autumn 2012
4.
The cohort of students (onwards) to which the module will be applicable.
September 2009 entrants onwards
5.
The number of students expected to take the module
131
6.
Modules to be withdrawn on the introduction of this proposed module and consultation
with other relevant Schools and Faculties regarding the withdrawal
None
7.
The level of the module (eg Certificate [C], Intermediate [I], Honours [H] or Postgraduate
[M])
7 [M]
8.
The number of credits which the module represents
30
9.
Which term(s) the module is to be taught in (or other teaching pattern)
Term 1 and 2
10. Prerequisite and co-requisite modules
A successful completion of all modules from stages 1- 3. The new stage 4, 30
credit AT1 module has been designed to underpin and enhance the acquisition
of core skills that pharmacy graduates require for professional practice. This
module will build upon previous clinical knowledge learned and applied in
PHAM1003 (Introduction to physiology & Pharmacology), PHAM1008
(Pharmacology & Therapeutics 1), PHAM1056 (Pharmacology & Therapeutics
2), PHAM1074 (Clinical Pharmacokinetics, Cancer Biology & Infection Control)
and the knowledge of medicines and practice gained from the professional
practitioner and patient modules PHAM1005 (Pharmacy Practice 1), PHAM1009
(Pharmacy Practice 2), and PHAM1013 (Pharmacy Practice 3). The module will
be delivered through a series of problem-based clinical sessions, workshops and
lectures focusing on clinical issues to consolidate students’ knowledge and skills.
11. The programmes of study to which the module contributes
Master of Pharmacy (B230)
12. The intended subject specific learning outcomes and, as appropriate, their relationship to
programme learning outcomes
This module covers key therapeutic areas that pharmacists are expected to have
knowledge of when dealing with patients who present with minor illnesses or
major diseases.
1
UNIVERSITY OF KENT
On successful completion of this module students will have:
1. Skills necessary for independent learning, problem analysis, oral
communication and confidently exercise initiative and personal responsibility
when taking decisions in complex and unpredictable situations (PO27, PO28,
PO29)
2. A comprehensive knowledge of the clinical pharmacology and therapeutic
uses of drugs (PO4, PO6, PO15-25)
3. An extensive knowledge of disease and minor ailments management and the
ability to apply and integrate knowledge gained from other areas of the
curriculum towards the provision of pharmaceutical care to patients PO38-41,
PO44-47)
4. An ability to undertake medication review taking account of patient, disease
and drug factors (PO 39-40, PO45)
5. Skills essential for the identification and resolution of drug therapy problems
(PO39-40, PO47)
6. An ability to develop pharmaceutical care plans for such patients (PO40-41,
PO45, PO53, PO56)
13. The intended generic learning outcomes and, as appropriate, their relationship to
programme learning outcomes
a. The ability to retrieve, analyse and evaluate information from text books,
primary research papers and review PO61, PO62, PO67, )
b. Enhanced problem solving (PO59, PO60, PO65, PO66, PO68, PO70)
c. The development of written communication skills (PO63, PO64)
d. Interpersonal skills (PO57)
e. Team working (PO58)
14. A synopsis of the curriculum
This module aims to further explore a range of common therapeutic topics which
pharmacists encounter in their everyday practice. Updates on major diseases will
cover the clinical pharmacology and therapeutic uses of drugs together with the
supporting evidence base for disorders of selected body systems. Students will
apply the knowledge previously gained in the pharmaceutical care of patients with
acute and long term conditions such as:
Eye (infections, glaucoma and tear deficiency)
Mouth (ulcers, oral thrush and cold sores)
Respiratory system (allergic rhinitis, asthma, COPD)
Skin (eczema, acne, psoriasis, wound management)
Cardiovascular system (management of cardiovascular risk and blood disorders)
Central nervous systems (pain, depression)
Travel medicine (malaria prophylaxis)
Endocrine (diabetes, metabolic syndrome and obesity, thyroid disorders,
glucocorticoids, mineralocorticoids, osteoporosis)
Genitourinary/reproductive systems (benign prostatic hyperplasia, erectile
dysfunction, urinary incontinence, HRT, contraception)
Common infections (bacterial, viral and fungal infections including urinary tract
infections and upper respiratory tract infections);
Gastrointestinal (dyspepsia, constipation, diarrhoea, Irritable Bowel Syndrome,
Inflammatory Bowel Disease, haemorrhoids and anti emetics)
Musculoskeletal system (arthritis, polymyalgia rheumatica, gout)
2
UNIVERSITY OF KENT
15. Indicative Reading List
ISBN Number
9780702029950
Author
Date
Rutter Paul
2009
Title
Publisher
Community Pharmacy
Symptoms, Diagnosis and
treatment
9780853699293
BMJ/RPSGB
0443071373
Walker, R. &
Whittlesea, C.
2011
2007
Churchill
Livingstone
British National Formulary,
61st Edition
Pharmaceutical
Press
Clinical Pharmacy and
Therapeutics,
4th edition
Churchill
Livingstone
16. Learning and Teaching Methods, including the nature and number of contact hours and
the total study hours which will be expected of students, and how these relate to
achievement of the intended learning outcomes(SSLO 12.1-12.6)
Directed Learning and Teaching Activities
Activity
Therapeutics
Revision
Seminars*
Interim
assessment
Formal
assessment
Total hours
Lectures
Workshop
(40 students)
22
7 x 3h
Clinical
Sessions
(all students)
24 x 3h
MSCL/
Private
Study
174h
Total hours
289
4
4
3
22
21
72
174
300
Clinical sessions: these interactive sessions will adopt a patient-focussed
approach with students being provided with an extensive range of clinical
scenarios (role play and workbook) to assist in their development of disease
management and problem solving skills. A major component of these sessions is
the set homework where students will be expected to retrieve, analyse and
evaluate information from relevant sources.
Lectures: these updates on major diseases will cover the clinical pharmacology
and therapeutic uses of drugs together with the supporting evidence base for
disorders of selected body systems. The topics covered in these lectures are
further explored in workshops.
Workshops: students are provided a variety of case studies and prescriptions
that pharmacists encounter in practice. They are expected to work in small
groups to explore the drug therapy problems, identify goals of therapy and make
appropriate recommendations to solve these clinical cases and deliver a
pharmaceutical care plan.
17. Assessment methods and how these relate to testing achievement of the intended
learning outcomes
Coursework (40%)
All the generic learning outcomes as well as SSLO12.1 and SSLO12.3 will be
continuously assessed through problem solving homework (10%) that will be set
and marked during term one.
3
UNIVERSITY OF KENT
Furthermore the BNF based interim assessment (30%) will assess students’
knowledge of disease and minor ailments management.
SSLO 12.1to 12.5 will be assessed by a one-hour Objective Structured Clinical
Examination ((OSCE, Pass/Fail).
Examination (60%)
Generic learning outcomes 13 a-c and SSLO 12.2, SSLO12.4 and SSLO 12.6 will
also be assessed by written examination and General Pharmaceutical Council
style multi-format MCQs.
This assessment strategy ensures that the core areas of applied therapeutics are
formally assessed and students are well prepared for pre-registration training and
professional practice.
Assessment Details
Methods
Assessment
of
Learning
outcomes
Weighting
Outline Details
%
assessed
All learning
outcomes
30%
BNF based Interim assessment (2h)
Continuous
Assessment:
All learning
outcomes
Pass/Fail
OSCE (1h)
Continuous
Assessment:
All learning
outcomes
10%
3 continuous assessments
Examination
All learning
60%
1 x 3 hour examination (includes MCQs)
Continuous
Assessment:
Clinical
sessions
outcomes
Pass Mark: The pass mark for this module is 40% overall.
18. Implications for learning resources, including staff, library, IT and space
No additional resources are required
19. The School/Collaborative Partner (delete as applicable) recognises and has embedded
the expectations of current disability equality legislation, and supports students with a
declared disability or special educational need in its teaching. Within this module we will
make reasonable adjustments wherever necessary, including additional or substitute
materials, teaching modes or assessment methods for students who have declared and
discussed their learning support needs. Arrangements for students with declared
disabilities will be made on an individual basis, in consultation with the
University’s/Collaborative Partner’s (delete as applicable) disability/dyslexia support
service, and specialist support will be provided where needed.
4
UNIVERSITY OF KENT
With regard to the applied therapeutics module, the curriculum, learning and
teaching methods and forms of assessment do not present any non-justifiable
disadvantages to students with disabilities.
If the module is part of a programme in a Partner College or Validated Institution,
please complete the following:
20. Campus(es) where module will be delivered:
Medway campus
21. Partner College / Validated Institution:
22. University School (for cognate programmes) or Faculty (for non-cognate programmes)
responsible for the programme:
Medway School of Pharmacy
SECTION 2: MODULE IS PART OF A PROGRAMME OF STUDY IN A UNIVERSITY
SCHOOL
Statement by the School Director of Learning and Teaching/School Director of
Graduate Studies (as appropriate): "I confirm I have been consulted on the above module
proposal and have given advice on the correct procedures and required content of module
proposals"
Bugewa Apampa
3 December 2012
................................................................
Date
Director of Learning and Teaching
…………………………………………………
Print Name
Statement by the Head of School: "I confirm that the School has approved the introduction
of the module and, where the module is proposed by School staff, will be responsible for its
resourcing"
Prof Iain Cumming
3 December 2012
..............................................
Date
.................................................................
Head of School
…………………………………………………….
Print Name
SECTION 3: MODULE IS PART OF A PROGRAMME IN A PARTNER COLLEGE OR
VALIDATED INSTITUTION
(Where the module is proposed by a Partner College/Validated Institution)
5
UNIVERSITY OF KENT
Statement by the Nominated Officer of the College/Validated Institution (delete as
applicable): "I confirm that the College/Validated Institution (delete as applicable) has
approved the introduction of the module and will be responsible for its resourcing"
.................................................................
Nominated Responsible Officer
College/Validated Institution
of
..............................................
Partner
………………………………………………….
Print Name
…………………………………………………..
Post
………………………………………….
Partner College/Validated Institution
Module Specification Template
Last updated January 2012
6
Date